Searching in the maze: sodium–glucose cotransporter-2 inhibitors in kidney transplant recipients to improve survival
Laia Oliveras, Núria Montero, Josep M. Cruzado
Abstract
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) improve cardiovascular and renal outcomes in chronic kidney disease patients with and without diabetes. Kidney transplant recipients have been excluded from landmark trials using SGLT2is and literature on safety and efficacy are scarce. Recent studies suggest that the SGLT2i use in kidney transplant recipients with diabetes is safe, paving the way to investigate whether SGLT2is could also reduce cardiovascular events and kidney function deterioration in kidney allograft recipients.
Topics & Concepts
MedicineDiabetes mellitusKidneyRenal functionKidney transplantKidney diseaseKidney transplantationUrologyCotransporterIntensive care medicineInternal medicineSodiumEndocrinologyOrganic chemistryChemistryRenal Transplantation Outcomes and TreatmentsDiabetes Treatment and ManagementPotassium and Related Disorders